MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
Taxane therapy remains the standard of care for triple-negative breast cancer. However, high frequencies of recurrence and progression in treated patients indicate that metastatic breast cancer cells can acquire resistance to this drug. The actin regulatory protein MENA and particularly its invasive...
| Main Authors: | , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
American Association for Cancer Research (AACR)
2018
|
| Online Access: | http://hdl.handle.net/1721.1/116423 https://orcid.org/0000-0001-6988-4260 https://orcid.org/0000-0002-0050-989X https://orcid.org/0000-0003-3214-4554 |